Prostera

Prostera

terazosin

Manufacturer:

Lek Pharma

Distributor:

Distriphil

Marketer:

Distriphil
Concise Prescribing Info
Contents
Terazosin HCl dihydrate
Indications/Uses
Mild to moderate HTN. Symptomatic treatment of urinary obstruction caused by BPH.
Dosage/Direction for Use
Adult HTN Initially 1 mg at bedtime, not exceeding during the 1st wk of treatment. Dose can be increased by approx doubling the dose at wkly intervals until effective control of BP. Maintenance dose: 2 mg daily. Max: Not exceeding 20 mg. Symptomatic treatment of urinary obstruction caused by BPH Initially 1 mg at bedtime for 7 days & should not be exceeded during the 1st wk of treatment. May increase dose to 2 mg daily for 14 days, followed by 5 mg daily for 7 days. Usual dose: 5 mg once daily. Max daily dose: 10 mg once daily.
Administration
May be taken with or without food: Swallow whole, do not chew.
Contraindications
Hypersensitivity to terazosin, or to a structurally similar α-adrenergic antagonist.
Special Precautions
History of micturition syncope. Syncopal episodes may occur w/in 30-90 min of the initial dose. Dizziness, light-headedness or fainting may occur when standing up quickly from a lying or sitting position. 1st dose effect: orthostatic hypotension. Vol depletion, restricted salt-intake, advanced age; known susceptibility to developing hypotension; cardiac conditions eg, pulmonary edema due to aortic or mitral stenosis, high-output cardiac insufficiency, right ventricular heart failure caused by pulmonary embolism or pericardial effusion, left ventricular heart failure w/ low filling pressure. Intraoperative floppy iris syndrome (IFIS) during cataract surgery. Do not use on patients w/ reduced urinary outflow or anuria or advanced renal deficiency. Caution in patients w/ impaired liver function & severe hepatic dysfunction. May have a major influence to drive & use machines.
Adverse Reactions
Headache, dizziness; vertigo; asthenia. Sinusitis; nervousness; paraesthesia, somnolence; blurred vision; palpitations, tachycardia; orthostotic hypotension; dyspnoea, nasal congestion; nausea; pain in extremities, back pain; erectile dysfunction; peripheral edema, fatigue, edema in the mucosa.
Drug Interactions
Significant hypotension w/ other antihypertensive agents; diuretics. Not recommended in combination w/ α-receptor blockers. Increased antihypertensive effect w/ vasodilators & nitrates. Reduced antihypertensive effect w/ sympathomimetics. Reduced BP & vascular reactions w/ dopamine, ephedrine, epinephrine, metaraminol, methoxamine & phenylephrine. May influence plasma renin activity & urinary excretion w/ vanillylmandelic acid. Reduces hypertensive effect of clonidine IV.
MIMS Class
Drugs for Bladder & Prostate Disorders / Other Antihypertensives
ATC Classification
G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Presentation/Packing
Form
Prostera tab 2 mg
Packing/Price
30's;90's
Form
Prostera tab 5 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in